In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
501 News Items found
Smiling female doctor talking to patient.
Q&A
6 Questions Answered about the CDH1 Gene Mutation & Stomach Cancer

Inheriting a mutation in the CDH1 gene can raise risk of a rare stomach cancer called hereditary diffuse gastric cancer.
physiatrist Jesuel Padro-Guzman
Q&A
Answers to 8 FAQ About Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Peripheral neuropathy is a common side effect of many types of chemotherapy. Learn about what it is, why it happens, and how to treat CIPN.
MSK medical oncologist Eileen O'Reilly with a patient
In the News
ASCO 2019: PARP Inhibitors Benefit People with Pancreatic Cancer Who Have a BRCA Mutation

Results from a large phase III clinical trial unveiled at this year’s ASCO meeting identify an effective targeted therapy for a subset of people with pancreatic cancer.
cryo-EM picture of mTORC1
In the Lab
Scientists Unlock Structure of mTOR, a Key Cancer Cell Signaling Protein

Structural biologists in the Sloan Kettering Institute have used a powerful tool called cryo-EM to solve the structure of a major cancer player.
Pictured: Ashley Landay (left) and Ashley Pildis (right)
Feature
A Tale of Two Ashleys: Meet a Nurse and a Patient Teaming Up for the New York City Marathon

Read about Ashley Landay, a breast cancer patient at MSK, who will run the TCS New York City Marathon with her chemotherapy nurse, Ashley Pildis.
MSK thoracic surgeon Alexis Chidi
In the Clinic
Six Things You Need to Know About Lung Cancer Screening and CT Scans

Find out why people at risk of lung cancer are not getting screened and why they should.
CAR T cell therapy
In the Clinic
CAR T Cell Therapies Are a Growing Area of Research

Cell therapies that use patients’ own immune cells to attack cancer — including CAR T cell therapy, an approach developed at MSK — are a promising and rapidly growing area of research.
David Hyman and Robin Gillespie
Finding
#AACR17: Basket Trial for Experimental Drug Shows Promising Early Results

Neratinib, which targets mutations that drive cancer growth, is showing promise for treating several types of cancer.
scale
Q&A
Why Are More Young Adults Getting Cancer? Obesity May Be to Blame

Cancer among younger Americans is on the rise, and much of it is linked to obesity. An MSK expert on diet and cancer explains what’s behind this disturbing new trend.
Dr. Alexander Drilon
FDA Grants Accelerated Approval to Repotrectinib for Cancers with NTRK Fusions 

The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.